Opus Genetics, Inc. IRD

IRD Company Overview

Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company focused on developing gene therapies and pharmaceutical treatments for inherited retinal diseases (IRDs) and other eye disorders. The company operates within the biotechnology and ophthalmology sectors, with a primary emphasis on adeno-associated virus (AAV)-based gene therapy programs targeting rare retinal conditions that can lead to blindness or severe vision impairment. Its pipeline includes therapies designed to address mutations associated with inherited retinal degeneration, while the company also maintains programs involving pharmaceutical candidates for retinal and refractive eye conditions.

The company’s current structure emerged through the combination of Ocuphire Pharma, Inc. and Opus Genetics, which expanded the organization’s focus from pharmaceutical ophthalmic products into inherited retinal gene therapy development. Opus Genetics positions itself within the rare-disease ophthalmology market, where regulatory incentives, orphan-drug pathways, and specialized clinical expertise can provide competitive advantages. Its customer and stakeholder base primarily includes retinal specialists, academic medical centers, patients with rare inherited eye diseases, and biotechnology investors focused on precision medicine and ophthalmic therapeutics.